A30.1
Tuberculoid leprosy
Clinical Classification Guidelines
Inclusion Terms
- TT leprosy
Medical Intelligence & Overview
Tuberculoid leprosy, classified under ICD-10 code A30.1, is a form of leprosy characterized by localized skin lesions and nerve damage. It is a milder manifestation of the disease, typically presenting with well-defined patches of skin that may be numb due to nerve involvement. This form is often seen in the early stages of leprosy and can be effectively managed with appropriate treatment. Recognized as TT leprosy, tuberculoid leprosy highlights the immune system's ability to contain the infection better than other forms of the disease.
Causes & Symptoms
Clinical Causes: Infection with *Mycobacterium leprae*, a slow-growing bacteria specific to leprosy Close and prolonged contact with an untreated individual infected with *Mycobacterium leprae* Transmission primarily occurs through respiratory droplets expelled by infected persons Genetic susceptibility may influence the likelihood of developing the disease Environmental factors, such as living in areas with poor sanitation and hygiene, can increase risk
Key Symptoms: Presence of one or several well-defined, hypopigmented or reddish skin patches that are dry and numb Loss of sensation in affected skin areas, leading to decreased touch, pain, and temperature sensitivity Nerve thickening or enlargement, especially in superficial nerves near skin lesions Muscle weakness in cases where nerve damage is severe Absence of significant systemic symptoms; generally limited to skin and nerves Rarely, initial symptoms may include minor discomfort or itching in affected areas
Diagnostic & Treatment
Diagnosis Path: Diagnosis of tuberculoid leprosy involves a combination of clinical examination and laboratory tests. Healthcare providers look for characteristic skin lesions with sensory loss and nerve thickening. Skin smears and biopsies can be performed to identify *Mycobacterium leprae*. However, in tuberculoid leprosy, bacterial load is typically low, making microscopy less reliable. Serologic tests are often not used due to limited sensitivity. The diagnosis is primarily clinical, supported by histopathological examination showing granulomatous inflammation with nerve involvement.
Treatment Protocols: Treatment for tuberculoid leprosy involves multi-drug therapy (MDT) as recommended by global health authorities. The standard regimen includes:
Clinical Advice & FAQs
Billing Guidance
Is A30.1 a billable ICD-10 code?
Yes, A30.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A30.1?
Clinical documentation must specify the nature of Tuberculoid leprosy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference